Looks like there is another wildcard in the mix: Merck R&D development leader, Roger Perlmutter.

He is retiring with Frazier. I just came across his name in this article from June:

https://www.bloomberg.com/news/articles/2019-...essor-hunt

Quote:

---

But now, Merck is laying the groundwork for his exit, as well as that of its seasoned research and development leader Roger Perlmutter , who is 66. At the same time, sales of Keytruda are beginning to mature, leading some investors to ask where the drug giant’s future growth will come from.

---